Outpatient Left Ventricular Assist Device Support: A Destination Rather Than a Bridge

Catanese, Katharine A.; Goldstein, Daniel J.; Williams, Deborah; Foray, Ann T.; Illick, Christopher D.; Gardocki, Michael; Weinberg, Alan; Levin, Howard R.; Rose, Eric A.; Öz, Mehmet C.

doi:10.1016/s0003-4975(96)00456-0

Cited by 75 publications

(27 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, from the mid 1980s, the focus of VAD development shifted to left ventricular support without heart resection, and left ventricular assist devices (LVADs) have since become a viable therapeutic approach as a bridge to cardiac transplantation (BTT) [3,4]. LVADs provide effective BTT therapy for patients with end-stage heart failure, and are increasingly used for destination therapy (DT) [5][6][7]. Recently, reports of patients weaned from LVAD use due to recovery of cardiac function have also been increasing, and the concept of bridge to recovery (BTR) using an LVAD has become popular [8,9].…”

Section: Introductionmentioning

confidence: 99%

Current status of third-generation implantable left ventricular assist devices in Japan, Duraheart and HeartWare

Sawa

2014

Surg Today

View full text Add to dashboard Cite

Recently, left ventricular assist devices (LVADs) have become a viable therapeutic approach as a bridge to cardiac transplantation, as well as destination therapy or as part of the bridge to recovery. In Japan, paracorporeal pneumatic devices are the only choice for such therapy, as implantable LVADs are not yet generally available due to device lag, which represents a serious problem in this field. Clinical trials of four different continuous-flow pumps, both axial and centrifugal flow types, were completed at about the same time, and two of those devices, DuraHeart and EVAHEART, have already been approved for use in Japan. Thus, reports of advanced treatment for severe heart failure with these devices are expected. The DuraHeart (Terumo Heart, Ann Arbor, MI, USA) and another device named the HeartWare (HeartWare Inc, Miami Lakes, FL, USA) are so-called third-generation devices, as they have achieved miniaturization and improvements in performance from the use of magnetic levitation. Based on our experiences from both clinical research and experimental use, we herein discuss the DuraHeart and HeartWare devices, with a focus on the clinical outcomes and management strategies. Because of the long waiting period for heart transplantation in Japan, these two devices are considered to have important roles in the near future for the treatment of severe heart failure, and a comprehensive strategy for LVAD therapy including such third-generation implantable devices is expected.

show abstract

Section: Introductionmentioning

confidence: 99%

Current status of third-generation implantable left ventricular assist devices in Japan, Duraheart and HeartWare

Sawa

2014

Surg Today

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4] Despite advances in LVAD device design and the overall success of this therapy, infection and sepsis continue to be among the most serious threats to long-term survival of patients with mechanical assist devices. [5][6][7][8] Both the large implanted surface area and the pooling of fluid that may surround the VAD can promote microbial adhesion and growth, and thereby facilitate infection.…”

mentioning

confidence: 99%

Effect of Left Ventricular Assist Device Infection on Post-transplant Outcomes

Schulman

Martens

Russo

et al. 2009

The Journal of Heart and Lung Transplantation

Self Cite

View full text Add to dashboard Cite

“…They have become the standard of care for orthotopic heart transplant (OHT) candidates by allowing for refractory HF normalizing hemodynamics, improving end-organ dysfunction, and providing a reasonable quality of life with a low incidence of major complications. [12][13][14][15][16][17][18][19] Over 70% of LVAD patients survive to OHT. 20 -23 Post-OHT outcomes of previous LVAD patients are similar to OHT patients who never received an LVAD before OHT.…”

mentioning

confidence: 99%